Skip to Content

Giapreza Approval History

FDA Approved: Yes (First approved December 21, 2017)
Brand name: Giapreza
Generic name: angiotensin II
Dosage form: Injection
Previous Name: LJPC-501
Company: La Jolla Pharmaceutical Company
Treatment for: Hypotension, Shock

Giapreza (angiotensin II) is a synthetic human angiotensin II vasoconstrictor indicated for the treatment of hypotension in adults with septic or other distributive shock.

Development History and FDA Approval Process for Giapreza

DateArticle
Dec 21, 2017Approval FDA Approves Giapreza (angiotensin II) to Treat Dangerously Low Blood Pressure
Aug 28, 2017La Jolla Pharmaceutical Company Announces U.S. FDA Acceptance of New Drug Application for LJPC-501
May 21, 2017Results of ATHOS-3 Phase 3 Study of LJPC-501 Published in The New England Journal of Medicine

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide